Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + COPDAC-28
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**Pembrolizumab + COPDAC-28** is a combination therapy used primarily in pediatric and young adult patients with high-risk classical Hodgkin lymphoma (cHL) who are slow early responders (SER) to frontline induction chemotherapy. Pembrolizumab is a monoclonal antibody immune checkpoint inhibitor targeting the programmed death-1 (PD-1) receptor, enhancing anti-tumor immunity by blocking inhibitory signaling in T cells. COPDAC-28 is a 28-day cycle chemotherapy regimen consisting of cyclophosphamide (an alkylating agent), vincristine (a microtubule inhibitor), prednisone (a corticosteroid), and dacarbazine (an alkylating agent). This combination is being studied for its ability to improve rapid and sustained responses while reducing long-term treatment toxicity, especially in a population at high risk for relapse after frontline therapy[1][2][4][7][9].
- Brand names
- Keytruda
- Other names
- pembrolizumab plus COPDAC-28pembrolizumab + cyclophosphamide + vincristine + prednisone + dacarbazine
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNAGR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on pembrolizumab + COPDAC-28.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + COPDAC-28.